Paid Clinical Trials Des Moines

Discover 51 paid clinical trials in Des Moines, Iowa. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 51

IVUS Guided TreatmentIMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Recruiting

Sponsor:

Medstar Health Research Institute

Location:

Des Moines IA, Minneapolis MN, Kankakee IL, Urbana ILshow 36 more

Code:

NCT04221815

Conditions

Atherosclerosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Eagle Eye Platinum digital IVUS catheter with optional SyncVision

Resolute Onyx Drug Eluting Stent

Onyx Frontier Drug Eluting Stent

Onyx TruStar Drug Eluting Stent

Onyx TruCor Drug Eluting Stent

Venetoclax with cBTKiA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period.

Recruiting

PHASE2

Sponsor:

Genentech, Inc.

Location:

Des Moines IA, Omaha NE, Grand Island NE, Springdale ARshow 15 more

Code:

NCT06524375

Conditions

Chronic Lymphocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Venetoclax

cBTKi Monotherapy

autoRICRemote Ischemic Conditioning Using the autoRIC

Recruiting

Sponsor:

CellAegis US, Inc.

Location:

Des Moines IA, Kansas City MO, West Bloomfield MI, Detroit MIshow 11 more

Code:

NCT03318575

Conditions

Ischemia-Reperfusion Injury

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

autoRIC

autoRIC Sham

Venetoclax & ObinutuzumabStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Recruiting

PHASE2

Sponsor:

AbbVie

Location:

Des Moines IA, Madison WI, Duluth MN, Detroit MIshow 7 more

Code:

NCT04895436

Conditions

Chronic Lymphocytic Leukemia (CLL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Venetoclax

Obinutuzumab

Venetoclax & ObinutuzumabA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Des Moines IA, Kansas City MO, Springfield IL, Dyer INshow 21 more

Code:

NCT06428019

Conditions

Chronic Lymphocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Venetoclax

Acalabrutinib

Obinutuzumab

Repotrectinib vs. CrizotinibA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Recruiting

PHASE3

Sponsor:

Bristol-Myers Squibb

Location:

Des Moines IA, Milwaukee WI, Toronto, Augusta GAshow 7 more

Code:

NCT06140836

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Repotrectinib

Crizotinib

Acalabrutinib & RituximabStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Recruiting

PHASE2

Sponsor:

AstraZeneca

Location:

Des Moines IA, Sioux Falls SD, Lexington KY, Detroit MIshow 9 more

Code:

NCT05952024

Conditions

Diffuse Large B-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Acalabrutinib

Rituximab

Navtemadlin & RuxolitinibStudy of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Recruiting

PHASE3

Sponsor:

Kartos Therapeutics, Inc.

Location:

Des Moines IA, Lincoln NE, Louisville KY, Nashville TNshow 22 more

Code:

NCT06479135

Conditions

Myelofibrosis

Post-PV MF

Post-ET Myelofibrosis

Primary Myelofibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Navtemadlin

Navtemadlin placebo

Ruxolitinib

Dara-VCD vs. ChemotherapyComparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Des Moines IA, Ankeny IA, Bellevue NE, Omaha NEshow 25 more

Code:

NCT06022939

Conditions

AL Amyloidosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Autologous Hematopoietic Stem Cell Transplantation

Biopsy

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Lenalidomide & NivolumabTesting the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Recruiting

PHASE1

Sponsor:

National Cancer Institute (NCI)

Location:

Des Moines IA, West Des Moines IA, Fort Dodge IA, La Crosse WIshow 35 more

Code:

NCT04609046

Conditions

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bone Marrow Aspiration and Biopsy

Computed Tomography

Echocardiography Test

Lenalidomide

Lumbar Puncture